The Contrast and Convergence of Bayesian and Frequentist Statistical Approaches in Pharmacoeconomic Analysis
暂无分享,去创建一个
[1] A O'Hagan,et al. Bayesian methods for design and analysis of cost-effectiveness trials in the evaluation of health care technologies , 2002, Statistical methods in medical research.
[2] L B Sheiner,et al. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. , 1982, Journal of pharmaceutical sciences.
[3] B. Bloom,et al. Classic or Bayesian research design and analysis. Does it make a difference? , 2002, International journal of technology assessment in health care.
[4] R. Klein,et al. A Bayesian approach to modelling the natural history of a chronic condition from observations with intervention. , 1999, Statistics in medicine.
[5] S. Sheingold. CAN BAYESIAN METHODS MAKE DATA AND ANALYSES MORE RELEVANT TO DECISION MAKERS? , 2001, International Journal of Technology Assessment in Health Care.
[6] J. Ware. Investigating Therapies of Potentially Great Benefit: ECMO , 1989 .
[7] D. Spiegelhalter,et al. Disease Mapping With WinBUGS and MLwiN, Bayesian Approaches to Clinical Trials and Health Care Evaluation , 2004 .
[8] J Lipscomb,et al. Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. , 1999, Journal of clinical epidemiology.
[9] E. J. PubMed Citation,et al. An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction , 2009 .
[10] S J Pocock,et al. The combination of randomized and historical controls in clinical trials. , 1976, Journal of chronic diseases.
[11] K Claxton,et al. An economic approach to clinical trial design and research priority-setting. , 1996, Health economics.
[12] David Lindley,et al. A Class of Utility Functions , 1976 .
[13] R J Lilford,et al. For Debate: The statistical basis of public policy: a paradigm shift is overdue , 1996, BMJ.
[14] Andrew H. Briggs,et al. Handling Uncertainty in Cost-Effectiveness Models , 2000, PharmacoEconomics.
[15] W Ray Kim,et al. Bayesian estimation, simulation and uncertainty analysis: the cost-effectiveness of ganciclovir prophylaxis in liver transplantation. , 2002, Health economics.
[16] G. N. Wilkinson. On Resolving the Controversy in Statistical Inference , 1977 .
[17] Stephen P. Brooks,et al. Markov chain Monte Carlo method and its application , 1998 .
[18] J. Berger,et al. Testing a Point Null Hypothesis: The Irreconcilability of P Values and Evidence , 1987 .
[19] Gerry Leversha,et al. Statistical inference (2nd edn), by Paul H. Garthwaite, Ian T. Jolliffe and Byron Jones. Pp.328. £40 (hbk). 2002. ISBN 0 19 857226 3 (Oxford University Press). , 2003, The Mathematical Gazette.
[20] J. Lewis,et al. Statistical principles for clinical trials (ICH E9): an introductory note on an international guideline. , 1999, Statistics in medicine.
[21] P. van den Broek,et al. Policy relevance of Bayesian statistics overestimated? , 2004, International Journal of Technology Assessment in Health Care.
[22] David M. Eddy,et al. Meta-analysis by the confidence profile method , 1992 .
[23] Adrian F. M. Smith,et al. Evidence-based medicine as Bayesian decision-making. , 2000, Statistics in medicine.
[24] John N. Tsitsiklis,et al. Introduction to Probability , 2002 .
[25] Eric R. Ziegel,et al. Statistical Issues in Drug Development , 1997 .
[26] M C Weinstein,et al. Bayesian value-of-information analysis. An application to a policy model of Alzheimer's disease. , 2001, International journal of technology assessment in health care.
[27] M. Stone,et al. Marginalization Paradoxes in Bayesian and Structural Inference , 1973 .
[28] D. Berry. Bayesian Statistics and the Efficiency and Ethics of Clinical Trials , 2004 .
[29] R J Lilford,et al. Who's afraid Of Thomas Bayes? , 2000, Journal of epidemiology and community health.
[30] J B Kadane,et al. Prime time for Bayes. , 1995, Controlled clinical trials.
[31] James O. Berger,et al. The interplay of Bayesian and frequentist analysis , 2004 .
[32] Charles M. Grinstead,et al. Introduction to probability , 1999, Statistics for the Behavioural Sciences.
[33] William E. Griffiths,et al. Bayesian Econometrics and How to Get Rid of Those Wrong Signs , 1988 .
[34] M. A. Best. Bayesian Approaches to Clinical Trials and Health‐Care Evaluation , 2005 .
[35] R. L. Winkler,et al. WHY BAYESIAN ANALYSIS HASN'T CAUGHT ON IN HEALTHCARE DECISION MAKING , 2001, International Journal of Technology Assessment in Health Care.
[36] A Gafni,et al. Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy. The Swiss HIV Cohort Study. , 1999, The Journal of antimicrobial chemotherapy.
[37] David R. Jones,et al. An introduction to bayesian methods in health technology assessment , 1999, BMJ.
[38] Daniel F Heitjan,et al. Bayesian estimation of cost-effectiveness: an importance-sampling approach. , 2004, Health economics.
[39] T. Bayes. An essay towards solving a problem in the doctrine of chances , 2003 .
[40] K Claxton,et al. Redefining the analytical approach to pharmacoeconomics. , 1999, Health economics.
[41] R. Chisin. Cost-Effectiveness Analysis , 2009, Journal of Nuclear Medicine.
[42] H. Jeffreys,et al. Theory of probability , 1896 .
[43] S. Goodman. Toward Evidence-Based Medical Statistics. 1: The P Value Fallacy , 1999, Annals of Internal Medicine.
[44] M C Weinstein,et al. The FDA's regulation of health economic information. , 2000, Health affairs.
[45] S. Holm. A Simple Sequentially Rejective Multiple Test Procedure , 1979 .
[46] Y. Shih. Bayesian approach in pharmacoeconomics: relevance to decision-makers , 2003, Expert review of pharmacoeconomics & outcomes research.
[47] M. Degroot. Optimal Statistical Decisions , 1970 .
[48] M. Bala,et al. ESTIMATING THE BAYESIAN LOSS FUNCTION , 2001, International Journal of Technology Assessment in Health Care.
[49] David Lindley,et al. Statistical Decision Functions , 1951, Nature.
[50] N. Zethraeus,et al. Definition, interpretation and calculation of cost-effectiveness acceptability curves. , 2000, Health economics.
[51] M. Drummond,et al. A rational framework for decision making by the National Institute For Clinical Excellence (NICE) , 2002, The Lancet.
[52] Christian P. Robert,et al. The Bayesian choice , 1994 .
[53] A Simple Problem with Strikingly Different Frequentist and Bayesian Solutions , 1970 .
[54] L D Fisher,et al. Comments on Bayesian and frequentist analysis and interpretation of clinical trials. , 1996, Controlled clinical trials.
[55] Daniel L Gillen,et al. Bayesian evaluation of group sequential clinical trial designs , 2007, Statistics in medicine.
[56] David Papineau,et al. The Virtues of Randomization , 1994, The British Journal for the Philosophy of Science.
[57] J O Chinnis,et al. BAYESIAN COST-EFFECTIVENESS ANALYSIS , 2001, International Journal of Technology Assessment in Health Care.
[58] Ronald A. Howard,et al. Information Value Theory , 1966, IEEE Trans. Syst. Sci. Cybern..
[59] Sander Greenland,et al. Bayesian perspectives for epidemiological research: I. Foundations and basic methods. , 2006, International journal of epidemiology.
[60] D. Spiegelhalter. Incorporating Bayesian Ideas into Health-Care Evaluation , 2004 .
[61] J. Berger. Statistical Decision Theory and Bayesian Analysis , 1988 .
[62] Roger L Holder,et al. A Comparison of Bayesian and Maximum Likelihood Methods to Determine the Performance of a Point of Care Test for Helicobacter pylori in the Office Setting , 2003, Medical decision making : an international journal of the Society for Medical Decision Making.
[63] Dalene K Stangl,et al. Bridging the gap between statistical analysis and decision making in public health research , 2005, Statistics in medicine.
[64] Jeffrey H. Dorfman. Bayesian Economics Through Numerical Methods: A Guide to Econometrics and Decision-Making with Prior Information , 1997 .
[65] James O. Berger,et al. ESTIMATION OF QUADRATIC FUNCTIONS: NONINFORMATIVE PRIORS FOR NON-CENTRALITY PARAMETERS , 1998 .
[66] Jonathan A C Sterne,et al. Sifting the evidence—what's wrong with significance tests? , 2001, BMJ : British Medical Journal.
[67] A H Briggs,et al. A Bayesian approach to stochastic cost-effectiveness analysis. , 1999, Health economics.
[68] D B Dunson,et al. Commentary: practical advantages of Bayesian analysis of epidemiologic data. , 2001, American journal of epidemiology.
[69] R. Robinson. Economic Evaluation and Health Care Cost-effectiveness analysis , 2006 .
[70] J. Neyman,et al. Frequentist probability and frequentist statistics , 1977, Synthese.
[71] A H Briggs,et al. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. , 1997, Health economics.
[72] F. Harrell,et al. USING FULL PROBABILITY MODELS TO COMPUTE PROBABILITIES OF ACTUAL INTEREST TO DECISION MAKERS , 2001, International Journal of Technology Assessment in Health Care.
[73] Sj Senn. Consensus and controversy in pharmaceutical statistics. (With discussion) , 2000 .
[74] M. L. Eaton. Group invariance applications in statistics , 1989 .
[75] A. Goldberger,et al. On Pure and Mixed Statistical Estimation in Economics , 1961 .
[76] K J Rothman,et al. No Adjustments Are Needed for Multiple Comparisons , 1990, Epidemiology.
[77] Donald Geman,et al. Stochastic Relaxation, Gibbs Distributions, and the Bayesian Restoration of Images , 1984, IEEE Transactions on Pattern Analysis and Machine Intelligence.
[78] L. Joseph,et al. Placing trials in context using Bayesian analysis. GUSTO revisited by Reverend Bayes. , 1995, JAMA.
[79] A A Stinnett,et al. Net Health Benefits , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.
[80] Norman E. Breslow,et al. Biostatistics and Bayes , 1990 .
[81] W. Mcghan,et al. Principles of Pharmacoeconomics , 1990 .
[82] A H Briggs,et al. A BAYESIAN APPROACH TO STOCHASTIC COST-EFFECTIVENESS ANALYSIS , 2001, International Journal of Technology Assessment in Health Care.
[83] Ronald A. Howard,et al. Value of Information Lotteries , 1967, IEEE Trans. Syst. Sci. Cybern..
[84] A J Moskowitz,et al. Bayesian estimation of cost-effectiveness ratios from clinical trials. , 1999, Health economics.
[85] M J Al,et al. A Bayesian approach to economic analyses of clinical trials: the case of stenting versus balloon angioplasty. , 2000, Health economics.
[86] Sander Greenland. Response: Bayesian perspectives for epidemiological research , 2006 .
[87] Lawrence Joseph,et al. Placing Trials in Context Using Bayesian Analysis , 2009 .
[88] David J Spiegelhalter,et al. Bayesian approaches to multiple sources of evidence and uncertainty in complex cost‐effectiveness modelling , 2003, Statistics in medicine.
[89] L. Stein,et al. Probability and the Weighing of Evidence , 1950 .
[90] Bradley Efron. Controversies in the Foundations of Statistics , 1978 .
[91] A. W. F. Edwards,et al. A History of Likelihood , 1974 .
[92] Giovanni Parmigiani,et al. The Stroke Prevention Policy Model: Linking Evidence and Clinical Decisions , 1997, Annals of Internal Medicine.
[93] M. Sculpher,et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis , 2012, PharmacoEconomics (Auckland).
[94] A. Doucet,et al. Computational Advances for and from Bayesian Analysis , 2004 .
[95] D G Altman,et al. Bayesians and frequentists , 1998, BMJ.
[96] G. Skrepnek. Summary of Functional Forms Involving Logarithms for a Simple Regression Equation , 2005 .
[97] D. Qin. BAYESIAN ECONOMETRICS: The First Twenty Years , 1996, Econometric Theory.
[98] M. Sculpher,et al. Representing uncertainty: the role of cost-effectiveness acceptability curves. , 2001, Health economics.
[99] David R. Jones,et al. Bayesian methods in health technology assessment: a review. , 2000, Health technology assessment.
[100] David Lindley,et al. Theory and Practice of Bayesian Statistics , 1983 .
[101] G. Casella,et al. Statistical Inference , 2003, Encyclopedia of Social Network Analysis and Mining.
[102] D A Berry,et al. A case for Bayesianism in clinical trials. , 1993, Statistics in medicine.
[103] Gordon B. Hazen,et al. A Bayesian approach to sensitivity analysis. , 1999, Health economics.
[104] D. Bartholomew,et al. A comparison of some Bayesian and frequentist inferences. II. , 1965, Biometrika.
[105] P. Urbach,et al. The value of randomization and control in clinical trials. , 1993, Statistics in medicine.
[106] A O'Hagan,et al. A framework for cost-effectiveness analysis from clinical trial data. , 2001, Health economics.
[107] David Turner,et al. Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach. , 2004, Health economics.
[108] C. Schmid,et al. Why clinicians are natural bayesians , 2005, BMJ : British Medical Journal.
[109] Anthony O’Hagan,et al. Inference for the Cost-Effectiveness Acceptability Curve and Cost-Effectiveness Ratio , 2000, PharmacoEconomics (Auckland).
[110] L Leblond,et al. Some comments on misspecification of priors in Bayesian modelling of measurement error problems. , 1997, Statistics in medicine.
[111] Peter E. Kennedy. A Guide to Econometrics , 1979 .
[112] Joel B. Greenhouse,et al. [Investigating Therapies of Potentially Great Benefit: ECMO]: Comment: A Bayesian Perspective , 1989 .
[113] Stephen Senn. Consensus and Controversy in Pharmaceutical Statistics , 2000 .
[114] M. Cowles,et al. On the Origins of the . 05 Level of Statistical Significance , 2005 .
[115] Bradley P Carlin,et al. Comparison of Bayesian, classical, and heuristic approaches in identifying acute disease events in lung transplant recipients , 2004, Statistics in medicine.
[116] Chih-Hsiang Ho. Some Frequentist Properties of a Bayesian Method in Clinical Trials , 1991 .
[117] M J Al,et al. Costs, effects and C/E-ratios alongside a clinical trial. , 1994, Health economics.
[118] John C. Hershey,et al. Carrier Screening for Cystic Fibrosis , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.
[119] Jeffrey M. Wooldridge,et al. Introductory Econometrics: A Modern Approach , 1999 .
[120] K Claxton,et al. Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals. , 1999, Health economics.
[121] J. Cornfield. Recent methodological contributions to clinical trials. , 1976, American journal of epidemiology.
[122] S. Goodman,et al. Toward Evidence-Based Medical Statistics. 2: The Bayes Factor , 1999, Annals of Internal Medicine.
[123] A O'Hagan,et al. Bayesian cost‐effectiveness analysis from clinical trial data , 2001, Statistics in medicine.